JianyiBao completes tens of millions of yuan in A+ round financing, led by China Zhongji Investment

Recently, Beijing JianyiBao Technology Co., Ltd. (hereinafter referred to as "JianyiBao") announced the completion of tens of millions of yuan in Series A+ funding. This round of financing was led by China Zhongji Investment, with Weilai Capital, a subsidiary of Tomson Healthcare, participating in the follow-up investment. According to reports, this round of financing will be mainly used to further strengthen the company's core business and expand its nationwide patient channels. Previously, JianyiBao had received three rounds of financing from institutions such as Puhua Capital and Baidu Venture Capital in less than two years.

Established in 2017, Beijing JianyiBao is the first domestic comprehensive service platform systematically engaged in risk management and health management for people with pre-existing conditions. JianyiBao successfully connects pharmaceutical companies, medication scenarios, and financial insurance companies. Addressing pain points across these three sectors, JianyiBao leverages its professional, technological, and innovative core capabilities to jointly develop insurable insurance products for people with pre-existing conditions with insurance companies, solving the problem of health insurance for people with pre-existing conditions, actively undertaking and participating in the construction of a multi-level medical security system, and actively promoting the healthy development of society.

Since its establishment, JianyiBao has successively launched "XinYiBao", "XinNaoYiBao" (protection plans for patients with high blood pressure, high blood lipids, and high blood sugar), "JieLiBao" (protection plan for patients with multiple sclerosis), and YouJiaAi long-term anticancer insurance (post-operative insurance for thyroid cancer patients), etc., which are commercial insurance products targeting specific patients. These initiatives represent several industry firsts and have improved the situation for hundreds of thousands of patients who "become impoverished due to illness and relapse into poverty," bringing new hope for their lives.

Wu Fushun, Partner and Managing Director of China Zhongji Investment, introduced that investing in JianyiBao is a proactive move by Zhongji Capital in the greater health field, primarily considering three aspects:

First, the huge market population.

China currently has nearly 500 million people with pre-existing conditions and 300 million people with chronic diseases, but there are very few products on the market that can be insured by people with pre-existing conditions, making it difficult to meet the risk protection needs of this population.

Second, core innovation capabilities.

Currently, commercial health insurance products are severely homogenized, and most products use traditional sales channels, which cannot reach people with pre-existing conditions. Based on a deep understanding of the medical and insurance industries, JianyiBao continues to innovate in both product development and channel construction.

By creating a cooperation model between insurance products and industrial enterprises and pharmacy scenarios, it has successively launched many influential insurance products in the industry, sharing the burden for customers and providing accurate data for insurance companies. In terms of channels, JianyiBao has established cooperation with more than 30,000 pharmacies to accurately locate people with pre-existing conditions, forming an effective traffic entrance and channel moat, and locking in core customer groups.

Third, policy support.

Whether it is the release of the "tax-preferred health insurance" policy or the latest revised "Health Insurance Management Measures," it shows the state's support for in-depth innovation in commercial health insurance.

JianyiBao is deeply cultivating the market for people with pre-existing conditions, using model innovation to develop more new products to fill the current market gap, improve the medical and health service experience, and meet the health insurance needs of more people. In the future, it will also involve chronic disease management, reducing the claims rate while helping customers maintain health levels and reducing the burden on the medical system.

Wen Yuanhua, President and Partner of China Zhongji Investment, said that the public's pursuit of health is eternal, and we can also see that many excellent companies are constantly innovating and striving to fill the imbalance between medical service needs and the supply of medical and health services. China Zhongji Investment will continue to increase its investment in the greater health field in the future, helping the public enjoy more convenient and intimate medical services and contributing to the construction of a healthy China.